China Resources Pharmaceutical Group Limited

SEHK:3320 Rapporto sulle azioni

Cap. di mercato: HK$33.5b

China Resources Pharmaceutical Group Gestione

Gestione criteri di controllo 3/4

China Resources Pharmaceutical Group Il CEO è Xiaosong Bai, nominato in Jan2022, e ha un mandato di 2.83 anni. la retribuzione annua totale è CN¥ 3.60M, composta da 98.6% di stipendio e 1.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.003% delle azioni della società, per un valore di HK$ 1.06M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.8 anni e 4.1 anni.

Informazioni chiave

Xiaosong Bai

Amministratore delegato

CN¥3.6m

Compenso totale

Percentuale dello stipendio del CEO98.6%
Mandato del CEO2.8yrs
Proprietà del CEO0.003%
Durata media del management2.8yrs
Durata media del Consiglio di amministrazione4.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up

Oct 07
China Resources Pharmaceutical Group Limited's (HKG:3320) Shares Climb 34% But Its Business Is Yet to Catch Up

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

Aug 30
Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Jun 01
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%

May 13
Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%

China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697

Apr 28
China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Apr 14
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697

Mar 28
China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon

Jan 28
China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon

We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Dec 06
We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

Sep 07
Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?

Aug 02
Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?

With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case

May 26
With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case

These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

May 05
These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year

Apr 04
China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year

Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?

Jan 24
Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?

Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?

Dec 15
Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?

China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price

Oct 18
China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price

China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt

Aug 27
China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt

China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15

May 29
China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15

May 02
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15

China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's

Apr 07
China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's

China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet

Mar 31
China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet

Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?

Feb 21
Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

Dec 07
Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate

Nov 10
China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate

These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

Aug 29
These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?

Aug 03
Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?

Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?

May 03
Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?

Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?

Apr 12
Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?

Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Mar 17
Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Xiaosong Bai rispetto agli utili di China Resources Pharmaceutical Group?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

CN¥4b

Mar 31 2024n/an/a

CN¥4b

Dec 31 2023CN¥4mCN¥4m

CN¥4b

Sep 30 2023n/an/a

CN¥4b

Jun 30 2023n/an/a

CN¥3b

Mar 31 2023n/an/a

CN¥4b

Dec 31 2022CN¥2mCN¥2m

CN¥4b

Compensazione vs Mercato: La retribuzione totale di Xiaosong ($USD 496.88K ) è circa la media per le aziende di dimensioni simili nel mercato Hong Kong ($USD 497.28K ).

Compensazione vs guadagni: La retribuzione di Xiaosong è aumentata di oltre il 20% nell'ultimo anno.


AMMINISTRATORE DELEGATO

Xiaosong Bai (53 yo)

2.8yrs

Mandato

CN¥3,601,000

Compensazione

Mr. Xiaosong Bai serves as Non-Independent Director of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. since March 3, 2022. He serves as Executive Director and Chief Executive Officer at China Re...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Xiaosong Bai
CEO & Executive Director2.8yrsCN¥3.60m0.0032%
HK$ 1.1m
Ran Tao
VP & Executive Director3.2yrsCN¥2.94mNessun dato
Rong Deng
CFO & Executive Director1.4yrsNessun datoNessun dato
Lu Ge
Chief Information Officer & VP10.9yrsNessun datoNessun dato
Kwai Cheng
Company Secretaryless than a yearNessun datoNessun dato
Jianjun Wu
Vice Presidentno dataNessun datoNessun dato
Kai Qiu
Vice President of CR Pharma & Chairman of China Resources Boyano dataNessun datoNessun dato

2.8yrs

Durata media

53yo

Età media

Gestione esperta: Il team dirigenziale di 3320 è considerato esperto (durata media dell'incarico 2.8 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Xiaosong Bai
CEO & Executive Director2.8yrsCN¥3.60m0.0032%
HK$ 1.1m
Ran Tao
VP & Executive Director3.2yrsCN¥2.94mNessun dato
Rong Deng
CFO & Executive Directorless than a yearNessun datoNessun dato
Tingmei Fu
Independent Non-Executive Director8.4yrsCN¥270.00kNessun dato
Ruifang Jiao
Non-Executive Director2.8yrsNessun datoNessun dato
Kejian Zhang
Independent Non-Executive Director8.4yrsCN¥270.00kNessun dato
Kin Fun Kwok
Independent Non-Executive Director8.4yrsCN¥270.00kNessun dato
Yi Feng
Chairman of China Resources Double-Crane Pharmaceutical Co.5.9yrsNessun datoNessun dato
Wei Guo
Non-Executive Director1.8yrsNessun datoNessun dato
Mo Han Shing
Independent Non-Executive Director7.3yrsCN¥270.00kNessun dato
Yuewei Han
Chairman5.1yrsNessun dato0.0048%
HK$ 1.6m
Yongqiang Sun
Non-Executive Directorless than a yearNessun datoNessun dato

4.1yrs

Durata media

57yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 3320 sono considerati esperti (durata media dell'incarico 4.1 anni).